P2RY12 and coronary artery disorder: An early meta-analysis comprising 12 RCTs suggested that oral P2Y12 inhibitors significantly reduced the rate of ischemic events (OR = 0.85) without significantly increasing major bleeding in patients with coronary heart disease, and the risk/benefit ratio was particularly favorable for STEMI patients (OR = 0.77) [13].